Elevated Prostate Health Index (phi) and Biopsy Reclassification During Active Surveillance of Prostate Cancer

Elevated Prostate Health Index (phi) and Biopsy Reclassification During Active Surveillance of Prostate Cancer

The Prostate Health Index (phi) has been FDA approved for decision-making regarding prostate biopsy. Phi has additionally been shown to positively correlate with tumor volume, extraprostatic disease and higher Gleason grade tumors. Here we describe a case in which an elevated phi encouraged biopsy o...

Full description

Bibliographic Details
Main Authors: Darian Andreas, Jeffrey J. Tosoian, Patricia Landis, Sacha Wolf, Stephanie Glavaris, Tamara L. Lotan, Edward M. Schaeffer, Lori J. Sokoll, Ashley E. Ross
Format: Article
Language:English
Published: Elsevier 2016-07-01
Series:Urology Case Reports
Subjects:
Prostate cancer
Biomarkers
Active surveillance
Prostate biopsy
Online Access:http://www.sciencedirect.com/science/article/pii/S2214442016300407

Internet

http://www.sciencedirect.com/science/article/pii/S2214442016300407

Similar Items